GM3 synthase deficiency
GM3 synthase deficiency is characterized by recurrent seizures (epilepsy) and problems with brain development. Within the first few weeks after birth, affected infants become irritable and develop feeding difficulties and vomiting that prevent them from growing and gaining weight at the usual rate. Seizures begin within the first year of life and worsen over time. Multiple types of seizures are possible, including generalized tonic-clonic seizures (also known as grand mal seizures), which cause muscle rigidity, convulsions, and loss of consciousness. Some affected children also experience prolonged episodes of seizure activity called nonconvulsive status epilepticus. The seizures associated with GM3 synthase deficiency tend to be resistant (refractory) to treatment with antiseizure medications. [ https://ghr.nlm.nih.gov/condition/gm3-synthase-deficiency ]
Term info
- UMLS:CN204860 (MONDO:equivalentTo)
- Orphanet:171714 (OMIM:609056)
- UMLS:C1836824 (Orphanet:171714)
- GARD:0012059 (MONDO:equivalentTo)
- SCTID:722762005 (MONDO:equivalentTo)
- Orphanet:370938 (MONDO:equivalentObsolete)
- Orphanet:370933 (MONDO:equivalentTo)
- OMIM:609056 (Orphanet:370938/ntbt)
- DOID:0060470 (MONDO:equivalentTo)
disease_grouping, ordo_group_of_disorders
https://github.com/monarch-initiative/mondo/issues/5682
GM3 synthase deficiency is characterized by recurrent seizures (epilepsy) and problems with brain development. Within the first few weeks after birth, affected infants become irritable and develop feeding difficulties and vomiting that prevent them from growing and gaining weight at the usual rate. Seizures begin within the first year of life and worsen over time. Multiple types of seizures are possible, including generalized tonic-clonic seizures (also known as grand mal seizures), which cause muscle rigidity, convulsions, and loss of consciousness. Some affected children also experience prolonged episodes of seizure activity called nonconvulsive status epilepticus. The seizures associated with GM3 synthase deficiency tend to be resistant (refractory) to treatment with antiseizure medications.
http://identifiers.org/snomedct/722762005, https://omim.org/entry/609056, http://linkedlifedata.com/resource/umls/id/C1836824, http://purl.obolibrary.org/obo/Orphanet_370933, http://purl.obolibrary.org/obo/DOID_0060470, http://linkedlifedata.com/resource/umls/id/CN204860
http://purl.obolibrary.org/obo/MONDO_0005093, http://purl.obolibrary.org/obo/MONDO_0019288
epilepsy syndrome, infantile-onset symptomatic, salt-and-pepper syndrome, ST3GAL5-CDG, disorder of lactosylceramide alpha-2,3-sialyltransferase activity, infantile-onset symptomatic epilepsy syndrome - developmental stagnation - blindness, salt & pepper syndrome, lactosylceramide alpha-2,3-sialyltransferase activity disease, salt and pepper developmental regression syndrome, GM3 synthase deficiency, infantile-onset symptomatic epilepsy syndrome-developmental stagnation-blindness syndrome, SPDRS, Amish infantile epilepsy syndrome
salt and pepper mental retardation syndrome
MONDO:0018274